Lenomorelin
Also known as: RC-1291, Ghrelin mimetic
Synthetic form of the native ghrelin peptide. A potent appetite stimulant that regulates energy balance and stimulates growth hormone release. Research compound for metabolic studies.
Research Status
Preclinical/Research Phase
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Expected pharmacological effect of ghrelin agonism. Occurs within 30–60 minutes of administration. Typically resolves as the peptide is metabolized.
Ghrelin signaling can transiently elevate cortisol levels. Effect is usually mild and self-resolving. Monitor in protocols involving stress-sensitive endpoints.
May occur due to sympathomimetic effects of ghrelin signaling. Typically mild and transient. Monitor vital signs in research protocols.
Reported in some research subjects. Usually resolves within 15–30 minutes. Related to vasodilatory effects of ghrelin.
Localized erythema, swelling, or mild discomfort at the injection site. Minimize by rotating injection sites and using proper aseptic technique. Usually resolves within 24 hours.
Reported in some research protocols. Typically mild and transient. May be related to changes in intracranial pressure or metabolic effects.
Uncommon but reported in some subjects. Usually mild and self-resolving. May be related to rapid changes in appetite signaling.
Localized fat loss or thickening can occur with repeated injections at the same site. Prevent by rotating injection sites systematically and spacing injections at least 1 inch apart.
Ghrelin can transiently increase blood glucose in some individuals. Monitor glucose levels in research protocols, especially in subjects with metabolic dysfunction. Effect is usually mild and reversible.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 1-5 mcg/kg |
| Frequency | Research protocol dependent |
| Route | Subcutaneous |
Dosing varies by research protocol. Typical range 1–5 mcg/kg body weight. IV or SC administration. Research compound only — not approved for human use.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
Lenomorelin (RC-1291) is a synthetic ghrelin receptor agonist that mimics the action of native ghrelin, a hormone produced primarily in the stomach. It binds to the growth hormone secretagogue receptor (GHSR-1a) on the hypothalamus and anterior pituitary, triggering the release of growth hormone and stimulating appetite through central nervous system pathways. The peptide also enhances gastric motility and regulates energy homeostasis by modulating metabolic rate and nutrient utilization.
GHSR-1a Receptor Signaling
Lenomorelin binds to growth hormone secretagogue receptor type 1a on hypothalamic neurons and pituitary somatotrophs, activating intracellular calcium signaling and IP3 pathways that trigger GH release
Appetite Regulation (Hypothalamic NPY/AgRP Pathway)
Activation of GHSR-1a on neuropeptide Y and agouti-related peptide neurons in the lateral hypothalamus increases appetite signaling and food intake behavior
Energy Expenditure and Metabolic Rate
Ghrelin signaling modulates sympathetic nervous system activity and brown adipose tissue thermogenesis, influencing overall energy expenditure and metabolic homeostasis
Gastric Motility
Ghrelin acts on vagal afferent neurons and enteric neurons to enhance gastric contractions and promote gastric emptying, supporting digestive function
- Lenomorelin is a non-peptide ghrelin mimetic that crosses the blood-brain barrier more efficiently than native ghrelin
- It has a longer half-life than native ghrelin, allowing for sustained GHSR-1a activation in research protocols
- The peptide stimulates GH secretion in a dose-dependent manner and is not subject to feedback inhibition by somatostatin
- Lenomorelin increases both basal and pulsatile GH secretion patterns
- It promotes appetite and food intake through direct hypothalamic action, distinct from leptin or insulin signaling
Track your Lenomorelin research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Lenomorelin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.